TAVO™

Investigational Intratumoral Cancer Immunotherapy

OncoSec’s VLA: Visceral Lesion Applicator

OncoSec Presents Late-Breaking Abstracts on TAVO-PLUS at AACR Annual Meeting II

OncoSec Stands #TogetherAgainstCancer

News & Events

OncoSec Announces Initiation of a Phase 2 Study at the Moffitt Cancer Center to Evaluate the Combination of TAVO plus OPDIVO® as Neoadjuvant Therapy for Melanoma
August 27, 2020
OncoSec to Present at the LD 500 Virtual Conference on September 2, 2020
August 25, 2020

Featured Articles

Designed to Arm the Immune System to Fight Cancer

We are investigating the potential for our lead product candidate, TAVO, through the intratumoral administration of IL-12, to stimulate systemic immune response and to become an innovative and potentially transformative therapy option for the treatment of cancer.

Clinical Pipeline

Our core technology platform continues to advance through clinical trials for various cancers

Technology

Our plasmid DNA delivery platform is designed to boost the body’s immune system to target and attack cancer

Partnerships

We have a track record of establishing, operating and evolving high-performance partnerships globally

It's all about you

Visit our Patient Portal

New Approaches, New Hope

Learn More About Oncosec

“TAVO” IL-12

Fighting tumors directly.

Fran’s Story

Reclaiming Independence from Melanoma

“I was headed down a one-way street with a dead end.”